Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIRE-3: FOLFIRI + Cetuximab vs Bevacizumab in mCRC
NCT00433927Phase 3Unknown
- Sponsor
- Volker Heinemann
- Start
- Jan 2007
- Primary completion
- Apr 2014
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of KL-140 in metastatic colorectal cancer (mCRC) (2 arms), sponsored by Volker Heinemann. Primary endpoint: Objective Response Rate at 6 months. Status: unknown.
02
Drugs
KL-140
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT00433927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00433927.